title: The effects of moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3% treatment on corneal wound healing in pigmented rabbits following anterior keratectomy.
abstract: OBJECTIVE
  These studies examined corneal healing rates, Type-IV collagen and zonula occludens membrane-associated protein (ZO-1) expression, as well as aqueous PGE(2) and IL-1 beta concentrations in pigmented rabbits treated with either moxifloxacin 0.5%, gatifloxacin 0.3% or BSS following anterior keratectomy.
  
  
  METHODS
  Anterior keratectomy surgery was followed by topical administration with commercial ophthalmic formulations of either moxifloxacin or gatifloxacin or BSS (TID for 96 h). Images of the fluorescein-stained healing corneas were analyzed for wound area. At 48 or 96 h following surgery, aqueous humor samples were collected and analyzed for the inflammatory mediators PGE(2) and IL-1 beta using an ELISA. The corneas were subsequently evaluated using both scanning and transmission electron microscopy. In a second parallel study, corneas were evaluated at both 48 and 96 h for Type-IV collagen and ZO-1 expression using immunohistochemistry.
  
  
  RESULTS
  Fluorescein-stained corneal images at 96 h postsurgery demonstrated that 90% +/- 8% re-epithelialization for moxifloxacin, 81% +/- 14% for gatifloxacin, and 88 +/- 6% for BSS((R)) (P > 0.05). PGE(2 )levels in the aqueous humor of fluoroquinolone treated eyes were reduced at 48 h compared to BSS treated eyes. IL-1 beta was undetectable in all samples. No differences in Type-IV collagen or ZO-1 expression were observed between any treatment groups. There were no differences between groups in histological appearance or in ultrastructural healing processes.
  
  
  CONCLUSIONS
  These studies demonstrated that the commercial ophthalmic formulations of moxifloxacin and gatifloxacin were similar to each other in their effects on the levels of aqueous humor PGE(2) and rates of corneal wound re-epithelialization.
authors.affiliation: Preclinical Sciences, Alcon Research Ltd. (R9-7), Fort Worth, TX 76134-2099, USA. keven.williams@alconlabs.com
authors.forename: K Keven
authors.initials: KK
authors.lastname: Williams
authors.forename: Mitchell D
authors.initials: MD
authors.lastname: McCartney
authors.forename: Rebecca L
authors.initials: RL
authors.lastname: Rice
authors.forename: Martin B
authors.initials: MB
authors.lastname: Wax
authors.forename: Joseph W
authors.initials: JW
authors.lastname: Hiddemen
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology*; D003315:Cornea / Q000187:drug effects* / Q000473:pathology / Q000601:surgery / Q000648:ultrastructure; D048988:Corneal Surgery, Laser / Q000662:veterinary; D015232:Dinoprostone / Q000378:metabolism; D024841:Fluoroquinolones / Q000494:pharmacology*; D000077734:Gatifloxacin; D007150:Immunohistochemistry / Q000662:veterinary; D008854:Microscopy, Electron / Q000662:veterinary; D000077266:Moxifloxacin; D009883:Ophthalmic Solutions; D011804:Quinolines / Q000494:pharmacology*; D011817:Rabbits; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D009883:Ophthalmic Solutions; D011804:Quinolines; D015232:Dinoprostone; D000077734:Gatifloxacin; D000077266:Moxifloxacin